Another bispecific, humanized IgG1 antibody that may be underneath investigation is zenocutuzumab (MCLA-128), which functions by means of two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by using ADCC. MCLA-128 functions by using a ‘dock and block’ mechanism whereby 1 arm from the antibo